Detalhe da pesquisa
1.
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
N Engl J Med
; 388(22): 2058-2070, 2023 Jun 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37256976
2.
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
N Engl J Med
; 386(12): 1143-1154, 2022 03 24.
Artigo
Inglês
| MEDLINE | ID: mdl-35320644
3.
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
N Engl J Med
; 386(6): 556-567, 2022 02 10.
Artigo
Inglês
| MEDLINE | ID: mdl-35139274
4.
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
N Engl J Med
; 387(1): 9-20, 2022 07 07.
Artigo
Inglês
| MEDLINE | ID: mdl-35665782
5.
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol
; 25(5): 614-625, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38697155
6.
c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer.
Breast Cancer Res
; 26(1): 13, 2024 01 18.
Artigo
Inglês
| MEDLINE | ID: mdl-38238761
7.
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
Breast Cancer Res Treat
; 204(2): 237-248, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38112922
8.
Outcomes in Nonmetastatic Hormone Receptor-Positive HER2-Negative Pure Mucinous Breast Cancer: A Multicenter Cohort Study.
J Natl Compr Canc Netw
; : 1-9, 2024 May 14.
Artigo
Inglês
| MEDLINE | ID: mdl-38744306
9.
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.
Lancet Oncol
; 24(9): 1029-1041, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37657462
10.
A Survey of Practice Patterns for Clinical Nodal Staging Prior to Neoadjuvant Chemotherapy in Breast Cancer.
Oncologist
; 28(12): e1142-e1151, 2023 Dec 11.
Artigo
Inglês
| MEDLINE | ID: mdl-37279777
11.
Pembrolizumab for Early Triple-Negative Breast Cancer.
N Engl J Med
; 382(9): 810-821, 2020 02 27.
Artigo
Inglês
| MEDLINE | ID: mdl-32101663
12.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
N Engl J Med
; 382(7): 610-621, 2020 02 13.
Artigo
Inglês
| MEDLINE | ID: mdl-31825192
13.
Comparison of initial and sequential salvage brain-directed treatment in patients with 1-4 vs. 5-10 brain metastases from breast cancer (KROG 16-12).
Breast Cancer Res Treat
; 200(1): 37-45, 2023 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-37138198
14.
Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment.
Future Oncol
; 19(8): 559-573, 2023 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-37070653
15.
Preliminary Attainability Assessment of Real-World Data for Answering Major Clinical Research Questions in Breast Cancer Brain Metastasis: Framework Development and Validation Study.
J Med Internet Res
; 25: e43359, 2023 03 23.
Artigo
Inglês
| MEDLINE | ID: mdl-36951923
16.
A Retrospective Exploratory Analysis for Serum Extracellular Vesicles Reveals APRIL (TNFSF13), CXCL13, and VEGF-A as Prognostic Biomarkers for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Int J Mol Sci
; 24(21)2023 Oct 25.
Artigo
Inglês
| MEDLINE | ID: mdl-37958571
17.
The impact of race and ethnicity in breast cancer-disparities and implications for precision oncology.
BMC Med
; 20(1): 72, 2022 02 11.
Artigo
Inglês
| MEDLINE | ID: mdl-35151316
18.
HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis.
BMC Med
; 20(1): 105, 2022 03 17.
Artigo
Inglês
| MEDLINE | ID: mdl-35296300
19.
Trastuzumab deruxtecan for HER2+ advanced breast cancer.
Future Oncol
; 18(1): 7-19, 2022 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-34823373
20.
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer.
Future Oncol
; 18(32): 3563-3572, 2022 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-36382554